Novartis in the zone
Executive Summary
Novartis' hypertension programs have improved compliance by 50 percent, the firm reports during its Q4 earnings call Jan. 18. Novartis has enrolled 500,000 patients worldwide in its "BP Zone" compliance initiative, a part of its "category captainship" strategy to enhance its leadership position in the hypertension market. Novartis is offering patients assistance with managing blood pressure by offering blood pressure monitors, information services and an educational Web site (1"The Pink Sheet" Oct. 30, 2006, p. 13). "We believe based on our analysis that those patients which were enrolled and stayed on the program, the compliance rate was increased by 50 percent," CEO Thomas Ebeling says. "That's one of the reasons why our market share in the U.S. has recovered"...
You may also be interested in...
Novartis’ “Captainship” Program Produces More Hypertension Market Share
Nearly a year after introducing its "category captainship" strategy to enhance its leadership position in the market, Novartis is reporting its most successful quarter in the hypertension market
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.